香连丸联合四联疗法治疗幽门螺杆菌感染的临床疗效分析  

Analysis of the Clinical Efficacy of Xianglian Pill Combined with Quadruple Therapy in the Treatment of Helicobacter Pylori Infection

作　　者：黄捷 HUANG Jie(The Third District of Internal Medicine,Luoyuan County Hospital,Luoyuan,Fujian Province,350600 China)

机构地区：[1]福建省罗源县医院内科三区,福建罗源350600

出　　处：《中外医疗》2022年第11期84-87,共4页China & Foreign Medical Treatment

摘　　要：目的探讨香连丸联合四联疗法治疗幽门螺杆菌感染(Hp)的临床疗效。方法随机选取该院2019年1月—2020年12月就诊的120例Hp感染患者进行研究,依据随机双盲分组原则将患者分为两组,各60例。其中对照组采用常规四联方案治疗,观察组采用香连丸联合四联方案治疗。对比两组患者Hp治愈率、中医证候群评分及不良反应。结果观察组Hp治愈率为96.67%(58/60),高于对照组Hp治愈率83.33%(50/60),差异有统计学意义(χ^(2)=5.956,P<0.05)。治疗前两组患者中医证候群评分呕恶、泄泻、胃脘疼痛对比,差异无统计学意义(P>0.05);治疗后观察组呕恶、泄泻、胃脘疼痛积分(1.28±0.21)分、(0.82±0.14)分、(0.64±0.12)分低于对照组(1.95±0.32)分、(1.23±0.18)分、(0.95±0.16)分,差异有统计学意义(t=13.559、13.927、12.006,P<0.05)。两组患者药物不良反应对比,差异无统计学意义(P>0.05)。结论香连丸联合四联疗法治疗Hp感染的治愈率较高,并可缓解因Hp感染所致的胃肠功能紊乱证候群,并且该治疗方案安全性高。Objective To investigate the clinical efficacy of Xianglian Pill combined with quadruple therapy in the treatment of Helicobacter pylori infection(Hp).Methods 120 patients with Hp infection who visited the hospital from January 2019 to December 2020 were randomly selected for research.And divided the patients into two groups with 60 cases in each group according to the principle of random double-blind grouping.The control group was treated with conventional quadruple regimen,while the observation group was treated with Xianglian Pill combined with quadruple regimen.The Hp cure rate,TCM syndrome scores and adverse reactions were compared between the two groups.Results The Hp cure rate in the observation group 96.67%(58/60),was higher than the Hp cure rate in the control group 83.33%(50/60),the difference was statistically significant(χ^(2)=5.956,P<0.05).Before treatment,there was no statistically significant difference in TCM syndrome scores of nausea,diarrhea and epigastric pain between the two groups(P>0.05).After treatment,the scores of nausea,diarrhea,and epigastric pain in the observation group were(1.28±0.21)points,(0.82±0.14)points,and(0.64±0.12)points,which lower than those in the control group(1.95±0.32)points,(1.23±0.18)points,(0.95±0.16)points,the difference was statistically significant(t=13.559,13.927,12.006,P<0.05).There was no statistically significant difference in adverse drug reactions between the two groups(P>0.05).Conclusion Xianglian pills combined with quadruple therapy has a high cure rate in the treatment of HP infection,and can relieve gastrointestinal dysfunction syndrome caused by HP infection,and the treatment scheme is safe.

关 键 词：香连丸 幽门螺杆菌 肠道细菌 中医证候评分 感染 

分 类 号：R5[医药卫生—内科学]